BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022

Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI), a clinical-stage company, announced its abstract on the hospitalization burden of cirrhosis and ascites at The Liver Meeting 2022 to be held in Washington, DC from November 4-6, 2022. The poster presentation, titled U.S. Hospitalization Burden of Patients with Cirrhosis and Ascites Receiving Paracentesis, is scheduled for November 6, 2022, from 1:00-2:00pm. BioVie develops innovative therapies targeting neurological disorders and advanced liver disease. Notable products include NE3107 for Alzheimer’s and Parkinson’s diseases and BIV201 for treating refractory ascites.

CARSON CITY, Nev., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract characterizing the hospitalization burden of patients with cirrhosis and ascites and receiving treatment via paracentesis has been selected for presentation at The Liver Meeting 2022, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2022 will be held Washington, DC, from November 4-6, 2022.

Details of the poster presentation are as follows:

Poster: (Abstract # 3441)
Title: U.S. Hospitalization Burden of Patients with Cirrhosis and Ascites Receiving Paracentesis (Rika O. Mortimer, et al)
Date & Time: November 6, 2022 (1:00-2:00pm)

About BioVie
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative therapies to overcome unmet medical needs in chronic debilitating conditions. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of ERK and Nek (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028) and is targeting primary completion in mid-2023. An estimated six million Americans suffer from Alzheimer’s. A Phase 2 study of NE3107 in Parkinson’s disease (NCT05083260) is fully enrolled and expects to have topline data readout in December 2022. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2b study for the treatment of refractory ascites due to liver cirrhosis with top-line results anticipated in mid-2023. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not available in the US or Japan. For more information, visit http://www.bioviepharma.com/.

Forward-Looking Statements 
This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

For Investor Relations Inquiries: 

Contact:  Bruce Mackle  Managing Director  LifeSci Advisors, LLC  bmackle@lifesciadvisors.com

FAQ

What is the main topic of BioVie Inc.'s recent press release?

BioVie Inc.'s press release announces the selection of their abstract on the hospitalization burden of cirrhosis and ascites for presentation at The Liver Meeting 2022.

When and where will BioVie present their poster on cirrhosis and ascites?

BioVie will present their poster on November 6, 2022, from 1:00-2:00pm at The Liver Meeting 2022 in Washington, DC.

What is the title of the poster being presented by BioVie at The Liver Meeting 2022?

The title of the poster is U.S. Hospitalization Burden of Patients with Cirrhosis and Ascites Receiving Paracentesis.

What therapies is BioVie developing for neurological disorders?

BioVie is developing NE3107, a drug candidate targeting Alzheimer’s and Parkinson’s diseases by inhibiting neuroinflammation.

What is the status of BioVie's drug BIV201?

BIV201 is being evaluated in a Phase 2b study for refractory ascites due to liver cirrhosis and has received FDA Fast Track status.